Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 13 results
Sort by:
Filters: Author is Kelesidis, Theodoros  [Clear All Filters]
Found 13 results.
  Print   CSV
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

B

Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
McComsey GA, Moser C, Currier J, et al. "Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s." Clin. Infect. Dis.. 2016;62(7):853-62.
Kelesidis T, Moser CB, Johnston E, et al. "Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s." J. Acquir. Immune Defic. Syndr.. 2018;78(3):362-366.

C

Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Dirajlal-Fargo S, Moser C, Brown TT, et al. "Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s." Open Forum Infect Dis. 2016;3(3):ofw174.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.

D

Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.

O

Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.

P

Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.

S

Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AMarie. "Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332." Medicine (Baltimore). 2018;97(22):e10955.
Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AMarie, Aberg JA. "Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332." Inflammation. 2016;39(4):1354-62.